MedTrace Logo

Mycobiome Evaluation in Children With Autism & GI Symptoms

NCT03494088 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-05-14

No results posted yet for this study

Summary

This study's primary aim is to explore the potential differences in the gut mycobiome of children with autism spectrum disorder compared to otherwise healthy children. The secondary objective of this study is to evaluate whether the presence of specific species of fungi (e.g. Candida tropicalis, C. albicans, or Saccharomyces cerevisiae), in stool: 1) correlates with increased gastrointestinal symptoms; 2) correlates with evidence of increased behavioral problems (as assessed by the Aberrant Behavior Checklist or Social Responsiveness Scale-2); or 3) plays the same role as a constituent of commensal gut microflora as in normal controls. The scale indicates severity of social deficits in the autism spectrum as mild, moderate or severe. Additionally, the study aims to compare the fecal and oral fungi in these children because many fecal mycobiota are felt to originate in the oropharynx.

Conditions

  • Autism
  • Gastrointenstinal Symptoms

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • The University of Texas Health Science Center, Houston

    lead OTHER

Eligibility

Min Age
4 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-22
Primary Completion
2019-05-01
Completion
2019-05-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03494088 on ClinicalTrials.gov